Society of urologic oncology biotechnology forum: New approaches and targets for advanced prostate cancer

被引：5

作者：

Belldegrun, A ^{[1
]}

Bander, NH

Lerner, SP

Wood, DP

Pantuck, AJ

机构：

[1] Univ Calif Los Angeles, Sch Med, Dept Urol, Div Urol Oncol, Los Angeles, CA 90024 USA

[2] Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Urol Oncol, Ithaca, NY USA

[3] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA

[4] Wayne State Univ, Dept Urol, Detroit, MI USA

来源：

JOURNAL OF UROLOGY | 2001年 / 166卷 / 04期

关键词：

prostate; prostatic neoplasms; apoptosis; biotechnology; clinical trials;

D O I：

10.1016/S0022-5347(05)65760-6

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: We provide an overview of advances in molecular based therapeutic strategies for prostate cancer and summarize the studies presented at the Society of Urologic Oncology Biotechnology Forum in 2000. Materials and Methods: Three promising new treatment strategies are presented, and a critique of the advantages and limitations of each is offered by a leading expert in the field. Results: Treatment results and the current state of dendritic cell based immunotherapy, monoclonal antibody therapy and anti-apoptotic treatment approaches are presented. Conclusions: Currently patients with advanced prostate carcinoma have expanded therapeutic options available in the form of molecular based phases II and III clinical trials.

引用

页码：1316 / 1321

页数：6

共 15 条

[1]

EASTHAM JA, 1995, CANCER RES, V55, P5151

[2] Exsulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis [J].

Goluboff, ET ;

Shabsigh, A ;

Saidi, JA ;

Weinstein, IB ;

Mitra, N ;

Heitjan, D ;

Piazza, GA ;

Pamukcu, R ;

Buttyan, R ;

Olsson, CA .

UROLOGY, 1999, 53 (02) :440-445

[3] In situ gene therapy for adenocarcinoma of the prostate:: A phase I clinical trial [J].

Herman, JR ;

Adler, HL ;

Aguilar-Cordova, E ;

Rojas-Martinez, A ;

Woo, S ;

Timme, TL ;

Wheeler, TM ;

Thompson, TC ;

Scardino, PT .

HUMAN GENE THERAPY, 1999, 10 (07) :1239-1249

[4] Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results [J].

Huang, SM ;

Harari, PM .

INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) :259-269

[5]

ICHIKAWA T, 1991, CANCER SURV, V11, P35

[6] The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides [J].

Morelli, S ;

Delia, D ;

Capaccioli, S ;

Quattrone, A ;

Schiavone, N ;

Bevilacqua, A ;

Tomasini, S ;

Nicolin, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (15) :8150-8155

[7] PROSTATE TISSUE-SPECIFICITY OF THE PROSTATE-SPECIFIC ANTIGEN PROMOTER ISOLATED FROM A PATIENT WITH PROSTATE-CANCER [J].

PANG, S ;

TANEJA, S ;

DARDASHITI, K ;

COHAN, P ;

KABOO, R ;

SOKOLOFF, M ;

TSO, CL ;

DEKERNION, JB ;

BELLDEGRUN, AS .

HUMAN GENE THERAPY, 1995, 6 (11) :1417-1426

[8]

Pang S, 1997, CANCER RES, V57, P495

[9]

POSTLETHWAITE R, 1979, SCOT MED J, V18, P131

[10] The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs) [J].

Shiff, SJ ;

Rigas, B .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (04) :445-450

← 1 2 →